logo.png
Arch Biopartners Granted Pre-Ind Meeting With FDA for Candidate Drug to Prevent Acute Kidney Injury
March 21, 2018 08:00 ET | Arch Biopartners
TORONTO, March 21, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCBB:ACHFF), announced today that a Pre-Investigational New Drug (Pre-IND) meeting with...
logo.png
Arch Biopartners Closes $1.25M Non-Brokered Private Placement Financing
March 09, 2018 08:00 ET | Arch Biopartners
TORONTO, March 09, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) and (OTCBB:ACHFF), announced today it has closed the non-brokered private placement the...
logo.png
Arch Biopartners Announces Start of GMP Manufacturing for Metablok at CSBio
February 27, 2018 07:30 ET | Arch Biopartners
TORONTO, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners, Inc., (Arch or the Company) (TSX-V:ARCH) (OTCBB:ACHFF) a portfolio-based biotechnology company, today announced CSBio of Menlo Park,...
logo.png
Arch Biopartners Closes Convertible Note Financing
February 16, 2018 09:00 ET | Arch Biopartners
TORONTO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX-V:ARCH) (OTCBB:ACHFF) announced it has closed the non-brokered, unsecured convertible note (“Note”)...
logo.png
Arch Biopartners Arranges Convertible Note Financing
February 08, 2018 07:30 ET | Arch Biopartners
TORONTO, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture:ARCH) (OTCBB:ACHFF), announced it has arranged a non-brokered, unsecured convertible note...
logo.png
Arch Biopartners Announces Completion of GMP Manufacturing of AB569 and Start Date of Phase I Trial
December 06, 2017 10:08 ET | Arch Biopartners
TORONTO, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCBB:ACHFF) today announced that the good manufacturing practice (GMP) production...